Ten‑Eleven Translocation‑2 gene mutations: A potential new molecular marker in malignant gliomas (Review)

  • Authors:
    • Lei Yu
    • SongTao Qi
  • View Affiliations

  • Published online on: October 18, 2011     https://doi.org/10.3892/ol.2011.447
  • Pages: 7-10
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Alterations of the Ten‑Eleven Translocation‑2 (TET2) gene in myeloid malignancies and isocitrate dehydrogenase (IDH) gene mutations in gliomas and myeloid malignancies have recently been identified using molecular, comparative genomic hybridization and single nucleotide polymorphism array techniques. The mutations of the TET2 gene have been shown to be mutually exclusive with IDH1/2 mutations in acute myeloid leukemia (AML) and evidence has been found to provide a biochemical basis for the mutual exclusivity of IDH1/2 and TET2 gene mutations. Based on mounting evidence, we aimed to investigate whether TET2 mutations may be identified as novel mutations in malignant gliomas without IDH1/2 mutations, and indicate their possible significance in gliomas.

1. Introduction

Malignant gliomas, the most common and lethal brain tumors, exhibit a great deal of diversity in their location, pathology, genetic status and response to therapy. Nevertheless, survival for patients with glioblastoma, the most aggressive glioma, although individually variable, has recently improved in the last 5 years from an average of 10 to 14 months after diagnosis due to improvements in the standard of care (1). A comprehensive understanding of the genetic basis and pathology of gliomas has provided new information regarding biologically based tumor classification and has identified molecular prognostic biomarkers to improve the management of patients with gliomas. Over the past decades the application of sequencing, comparative genomic hybridization (CGH) and single nucleotide polymorphism (SNP) array techniques have revealed the molecular genetic background of neoplasms through the identification of novel oncogenes and tumor suppressor genes.

2. IDH1/2 mutations in gliomas and myeloid malignancies

One recently identified class of genes mutated in cancer are those coding for isocitrate dehydrogenase (IDH), which catalyzes the oxidative decarboxylation of isocitrate to α-ketoglutarate (α-KG) leading to NADPH production (2,3). The NADP+-dependent IDH1 (located in the cytoplasm and peroxisomes) and its mitochondrial counterpart IDH2 are mutated in up to 75% of grade II–III gliomas and secondary glioblastoma multiforme (GBM) as well as myeloid malignancies including primary and secondary acute myeloid leukemia (AML, 15–30%) and preleukemic clonal malignancies, such as myelodysplasia and myeloproliferative neoplasms (29). IDH1 mutation has rapidly emerged as a novel prognostic and diagnostic marker with which to identify low-grade gliomas and to distinguish secondary from primary GBM (4,10,11). IDH1/2 mutations are heterozygous, with tumors retaining one wild-type copy of the relevant IDH1 or IDH2 allele and producing single amino acid substitutions at arginine 132 (R132) in IDH1 or corresponding arginine 172 (R172) in IDH2 in glioma and leukemia, or at arginine 140 (R140) in IDH2 in leukemia (8,12). Notably, the R132 mutation in IDH1 results not only in a marked decrease of normal catalytic activity, but also in a gain of novel function catalyzing the NADPH+-dependent reduction of α-KG to R(-)-2-hydroxyglutarate (2-HG) (8,12). Decreased α-KG and α-KG-dependent prolyl hydroxylase (PHD) activity leads to an increase in hypoxia-inducible factor-1α (HIF-1α), since PHDs use α-KG as a substrate for a reaction that normally targets HIF-1α for degradation (13). α-KG reduction and D-2-HG accumulation cooperatively contribute to tumorigenesis (14), which may resolve the continuing controversy over whether mutant IDH1 is a tumor suppressor gene or an oncogene (15,16).

3. TET2 mutations in gliomas and myeloid malignancies

Other recently reported gene mutations are those of the Ten-Eleven Translocation-2 gene (TET2), which have been found in 20–26% of myelodysplastic syndromes or secondary AML (17,18), 14% of myeloproliferative neoplasms (17,19,20), and 12% of de novo AML (21). TET2 is a putative tumor suppressor gene located at chromosome 4q24, encoding a dioxygenase that converts 5-methylcytosine to 5-hydroxymethylcytosine, leading to DNA demethylation at selective loci. It has also been indicated in the regulation of normal myelopoiesis (2224), and the disruption of TET2 enzymatic activity favours myeloid tumorigenesis (24). Measurement of 5-hydroxymethylcytosine levels in myeloid malignancies may prove valuable as a diagnostic and prognostic tool to tailor therapies and assess responses to anticancer drugs (24). TET2 abnormalities are highly heterogeneous and inactivating showing a relatively diverse pattern of frame shift, nonsense, and missense mutations scattered across several of its exons. Additionally, TET2 may occur as hemizygous or heterozygous alterations, including loss of heterozygosity, due to hemizygous deletion or uniparental disomy (17,25). In contrast to the affirmatively prognostic value of IDH1 mutation in gliomas (4,26), the prognostic value of TET2 mutations in myeloid malignancies remains unclear (27). Similarly, survival in primary AML did not appear to be affected by the presence of IDH mutations (2,8,28).

4. Correlation between TET2 and IDH1/2 mutations

Mutations of TET2 gene have been shown to coexist with other pathogenetically relevant mutations, including the retinoic acid receptor α gene, thrombopoietin receptor gene (myeloproliferative leukemia, MPL), janus kinase 2 gene (JAK2), KIT gene, FMS-like tyrosine kinase 3 gene (FLT3), renin-angiotensin system (RAS) gene, mixed lineage leukemia (MLL) gene, CCAAT enhancer binding protein α gene (CEBA+) or nucleophosmin 1 gene (NHMI) (1821,29,30), but occur in a manner mutually exclusive with that of IDH1 and IDH2 genes in AML (30). Xu et al found that the expression of mutant IDH1/2 and D-2-HG inhibited the activity of TET2 in catalyzing the 5mC-to-5hmC conversion, which not only supported, but also provided a biochemical basis for the mutual exclusivity of IDH1/2 and TET2 gene mutations (14). The mechanisms of various gene mutations involved in disease initiation and/or progression are not isolated but associated, compatible or exclusive of each other. Considering the ubiquitous nature of mutant TET2 in myeloid malignancies, mutant IDH1/2 in gliomas and both mutations in myeloid malignancies, it may be possible that TET2 mutation is also present in malignant gliomas, particularly those without IDH1/2 mutation.

5. Discussion

Mounting evidence has indicated that TET2 alterations are a common event in a spectrum of myeloid malignancies, that IDH1/2 mutations are frequently present in gliomas, and that they both exhibit similar frequencies in myeloid malignancies. IDH1/2 mutations were mutually exclusive with mutations in the α-KG-dependent enzyme TET2, and TET2 loss-of-function mutations were associated with similar epigenetic defects to those of IDH1/2 mutants in AML. Expression of mutant IDH1/2 or TET2 depletion impaired hematopoietic differentiation and increased stem/progenitor cell marker expression, indicating a shared proleukemogenic effect (30). Additionally, the two mutations of IDH1 and TET2 have been reported to occur at a relatively early stage during glioma and leukemia development (17,18,31). These findings suggest that TET2 mutations may be identified as novel mutations in malignant gliomas without IDH1/2 mutations, since no reports are currently available regarding the association between TET2 mutations and malignant gliomas.

IDH1/2 mutations are concurrent with TP53 mutations in astrocytic tumors (9,31,32) and 1p19q codeletion in oligodendroglial tumors (9,32,33), but mutually exclusive with epidermal growth factor receptor (EGFR) amplification (34) and the BRAF fusion gene (10,35). IDH1/2 mutations are inversely associated with numerous characteristic genetic changes of primary glioblastomas, including EGFR amplification, cyclin-dependent kinase inhibitor 2A or 2B deletion, and phosphatase and tensin homolog mutations (9,32). IDH mutations do not increase in frequency in the progression to higher-grade gliomas and occur prior to other genetic changes, indicating that these mutations arise at some point in the transition from glial progenitor cells to a clinically evident tumor (9,31,32,36,37). Common genetic changes associated with various glioma subtypes are shown in Fig. 1 in addition to the hypothesis that TET2 mutations occur in gliomas. If the above-mentioned hypothesis holds true, several questions may be raised. The specific type of TET2 mutation in malignant gliomas remains to be identified. It is also unknown whether TET2 mutations are exclusive with IDH1/2 mutations in gliomas, or perhaps even concurrent with them. In instances where mutant TET2 coexists with IDH1/2 mutations or other mutations, it is currently unclear as to whether it predates or postdates their emergence. Within the context of a specific disease, it is likely that the presence of mutant TET2 affects phenotype, prognosis or treatment response. Finally, it is necessary to determine the pathogenetic contribution of mutant TET2 in cancer, particularly in view of its occurrence across different molecular profiles.

Further clinical investigation from different centers is required to confirm our hypothesis. Additional laboratory studies are required to clarify the biological consequence of these mutations prior to any clinical applications.

References

1 

Van Meir EG, Hadjipanayis CG, Norden AD, Shu HK, Wen PY and Olson JJ: Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma. CA Cancer J Clin. 60:166–193. 2010.PubMed/NCBI

2 

Mardis ER, Ding L, Dooling DJ, et al: Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med. 361:1058–1066. 2009. View Article : Google Scholar : PubMed/NCBI

3 

Parsons DW, Jones S, Zhang X, et al: An integrated genomic analysis of human glioblastoma multiforme. Science. 321:1807–1812. 2008. View Article : Google Scholar : PubMed/NCBI

4 

Kloosterhof NK, Bralten LB, Dubbink HJ, French PJ and van den Bent MJ: Isocitrate dehydrogenase-1 mutations: a fundamentally new understanding of diffuse glioma? Lancet Oncol. 12:83–91. 2011. View Article : Google Scholar : PubMed/NCBI

5 

Marcucci G, Maharry K, Wu YZ, et al: IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol. 28:2348–2355. 2010. View Article : Google Scholar

6 

Paschka P, Schlenk RF, Gaidzik VI, et al: IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. J Clin Oncol. 28:3636–3643. 2010. View Article : Google Scholar

7 

Tefferi A, Lasho TL, Abdel-Wahab O, et al: IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis. Leukemia. 24:1302–1309. 2010. View Article : Google Scholar

8 

Ward PS, Patel J, Wise DR, et al: The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell. 17:225–234. 2010. View Article : Google Scholar : PubMed/NCBI

9 

Yan H, Parsons DW, Jin G, et al: IDH1 and IDH2 mutations in gliomas. N Engl J Med. 360:765–773. 2009. View Article : Google Scholar : PubMed/NCBI

10 

Ducray F, El-Hallani S and Idbaih A: Diagnostic and prognostic markers in gliomas. Curr Opin Oncol. 21:537–542. 2009. View Article : Google Scholar : PubMed/NCBI

11 

Schiff D and Purow BW: Neuro-oncology: isocitrate dehydrogenase mutations in low-grade gliomas. Nat Rev Neurol. 5:303–304. 2009. View Article : Google Scholar : PubMed/NCBI

12 

Dang L, White DW, Gross S, et al: Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature. 462:739–744. 2009. View Article : Google Scholar : PubMed/NCBI

13 

Zhao S, Lin Y, Xu W, et al: Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha. Science. 324:261–265. 2009. View Article : Google Scholar : PubMed/NCBI

14 

Xu W, Yang H, Liu Y, et al: Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases. Cancer Cell. 19:17–30. 2011. View Article : Google Scholar : PubMed/NCBI

15 

Garber K: Oncometabolite? IDH1 discoveries raise possibility of new metabolism targets in brain cancers and leukemia. J Natl Cancer Inst. 102:926–928. 2010. View Article : Google Scholar : PubMed/NCBI

16 

Zhu J, Zuo J, Xu Q, Wang X, Wang Z and Zhou D: Isocitrate dehydrogenase mutations may be a protective mechanism in glioma patients. Med Hypotheses. 76:602–603. 2011. View Article : Google Scholar : PubMed/NCBI

17 

Delhommeau F, Dupont S, Della VV, et al: Mutation in TET2 in myeloid cancers. N Engl J Med. 360:2289–2301. 2009. View Article : Google Scholar : PubMed/NCBI

18 

Langemeijer SM, Kuiper RP, Berends M, et al: Acquired mutations in TET2 are common in myelodysplastic syndromes. Nat Genet. 41:838–842. 2009. View Article : Google Scholar : PubMed/NCBI

19 

Tefferi A, Levine RL, Lim KH, et al: Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates. Leukemia. 23:900–904. 2009. View Article : Google Scholar : PubMed/NCBI

20 

Tefferi A, Pardanani A, Lim KH, et al: TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis. Leukemia. 23:905–911. 2009. View Article : Google Scholar : PubMed/NCBI

21 

Abdel-Wahab O, Mullally A, Hedvat C, et al: Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood. 114:144–147. 2009. View Article : Google Scholar : PubMed/NCBI

22 

Ito S, D’Alessio AC, Taranova OV, Hong K, Sowers LC and Zhang Y: Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specification. Nature. 466:1129–1133. 2010. View Article : Google Scholar : PubMed/NCBI

23 

Tahiliani M, Koh KP, Shen Y, et al: Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science. 324:930–905. 2009. View Article : Google Scholar : PubMed/NCBI

24 

Ko M, Huang Y, Jankowska AM, et al: Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Nature. 468:839–843. 2010. View Article : Google Scholar : PubMed/NCBI

25 

Jankowska AM, Szpurka H, Tiu RV, et al: Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms. Blood. 113:6403–6410. 2009. View Article : Google Scholar : PubMed/NCBI

26 

Reitman ZJ and Yan H: Isocitrate dehydrogenase 1 and 2 mutations in cancer: alterations at a crossroads of cellular metabolism. J Natl Cancer Inst. 102:932–941. 2010. View Article : Google Scholar : PubMed/NCBI

27 

Tefferi A: Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia. 24:1128–1138. 2010. View Article : Google Scholar : PubMed/NCBI

28 

Chou WC, Hou HA, Chen CY, et al: Distinct clinical and biologic characteristics in adult acute myeloid leukemia bearing the isocitrate dehydrogenase 1 mutation. Blood. 115:2749–2754. 2010. View Article : Google Scholar : PubMed/NCBI

29 

Tefferi A, Lim KH, Abdel-Wahab O, et al: Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML. Leukemia. 23:1343–1345. 2009. View Article : Google Scholar : PubMed/NCBI

30 

Figueroa ME, Abdel-Wahab O, Lu C, et al: Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell. 18:553–567. 2010. View Article : Google Scholar

31 

Watanabe T, Nobusawa S, Kleihues P and Ohgaki H: IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol. 174:1149–1153. 2009. View Article : Google Scholar : PubMed/NCBI

32 

Ichimura K, Pearson DM, Kocialkowski S, et al: IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. Neuro Oncol. 11:341–347. 2009. View Article : Google Scholar : PubMed/NCBI

33 

Labussiere M, Idbaih A, Wang XW, et al: All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2. Neurology. 74:1886–1890. 2010. View Article : Google Scholar : PubMed/NCBI

34 

Sanson M, Marie Y, Paris S, et al: Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol. 27:4150–4154. 2009. View Article : Google Scholar : PubMed/NCBI

35 

Korshunov A, Meyer J, Capper D, et al: Combined molecular analysis of BRAF and IDH1 distinguishes pilocytic astrocytoma from diffuse astrocytoma. Acta Neuropathol. 118:401–405. 2009. View Article : Google Scholar : PubMed/NCBI

36 

Balss J, Meyer J, Mueller W, Korshunov A, Hartmann C and von Deimling A: Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol. 116:597–602. 2008. View Article : Google Scholar : PubMed/NCBI

37 

Ohgaki H and Kleihues P: Genetic alterations and signaling pathways in the evolution of gliomas. Cancer Sci. 100:2235–2241. 2009. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

January 2012
Volume 3 Issue 1

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Yu L and Yu L: Ten‑Eleven Translocation‑2 gene mutations: A potential new molecular marker in malignant gliomas (Review). Oncol Lett 3: 7-10, 2012
APA
Yu, L., & Yu, L. (2012). Ten‑Eleven Translocation‑2 gene mutations: A potential new molecular marker in malignant gliomas (Review). Oncology Letters, 3, 7-10. https://doi.org/10.3892/ol.2011.447
MLA
Yu, L., Qi, S."Ten‑Eleven Translocation‑2 gene mutations: A potential new molecular marker in malignant gliomas (Review)". Oncology Letters 3.1 (2012): 7-10.
Chicago
Yu, L., Qi, S."Ten‑Eleven Translocation‑2 gene mutations: A potential new molecular marker in malignant gliomas (Review)". Oncology Letters 3, no. 1 (2012): 7-10. https://doi.org/10.3892/ol.2011.447